Skip to Main content Skip to Navigation
Conference papers

The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer

Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01936152
Contributor : Mouniati Colo <>
Submitted on : Tuesday, November 27, 2018 - 11:48:55 AM
Last modification on : Wednesday, March 4, 2020 - 11:26:01 AM

Identifiers

  • HAL Id : hal-01936152, version 1

Collections

Citation

Wilfrid Finck, Judith Passildas, Camille Poirier, Fabrice Kwiatkowski, Catherine Abrial, et al.. The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer. Breast Cancer Symposium, Dec 2018, SAN ANTONIO, United States. ⟨hal-01936152⟩

Share

Metrics

Record views

57